1. Recent Updates in SLE

4. Program Goal

5. Sjögren Syndrome: Beliss Study

6. Beliss Study Results

7. Use of Belimumab in African American Patients

8. Early Response to Belimumab

9. Belimumab: Long-term Follow-up

10. Belimumab in Sicker Patients

11. PROMISSE: Adverse Pregnancy Outcomes Are Associated With LAC, Not Anticardiolipin

12. PROMISSE: Definition of LAC

13. Only LAC Is Associated With Pregnancy Loss

14. LAC Results

15. SLE Activity -- But NOT Serologies -- Associated With Pregnancy Loss

16. Background on Cardiovascular Disease

17. SLE Risk Model Results

18. 50-Year-Old Man With BMI 23, High SBP

19. Point-Based Risk Assessment

20. Comparison With Framingham Formula

21. HCQ as a Protective Factor for Thrombosis

22. HCQ Use and Risk of Thrombosis

23. Association Between Current HCQ Use and Thrombosis, Stratified by aPL Status

24. Current Prednisone Use and Risk of Thrombosis

25. NSAID Use and Risk of Thrombosis

26. Vitamin D Deficiency in Murine SLE: Immunomodulator

27. Vitamin D Deficiency in Human SLE

28. 20-Unit Increase in 25-Hydroxy Vitamin D

29. 25-Hydroxy Vitamin D Leads to Improvement in SBP

30. Allogeneic Mesenchymal Stem Cell Transplantation

31. Mechanism Involved With UC MSC

32. Rituximab and Cyclophosphamide

33. Blisibimod

34. Epratuzumab

36. Epratuzumab Status

37. Definition of P140

38. SRI in Lupuzor vs Fogerimod

39. Targeting the Innate Immune System: Anti-Interferons in Clinical Studies

40. Rontalizumab

41. Laquinimod

42. Abbreviations

43. Abbreviations (cont)